A Next-generation Genetically Attenuated Plasmodium falciparum Parasite Created by Triple Gene Deletion
Sebastian A Mikolajczak, Viswanathan Lakshmanan, Matthew Fishbaugher, Nelly Camargo, Anke Harupa, Alexis Kaushansky, Alyse N Douglass, Michael Baldwin, Julie Healer, Matthew O'Neill, Phuong Thuan, Alan Cowman, Stefan HI Kappe
Molecular Therapy | CELL PRESS | Published : 2014
Awarded by Foundation for the National Institutes of Health through the Grand Challenges in Global Health Initiative
Awarded by Telemedicine & Advanced Technology Research Center at Fort Detrick, MD
The research was partially funded by a Grant from the Foundation for the National Institutes of Health through the Grand Challenges in Global Health Initiative (Grant ID: 1481). This research and development program was also made possible by a cooperative agreement that was awarded and administered by the US Army Medical Research & Materiel Command and the Telemedicine & Advanced Technology Research Center, at Fort Detrick, MD, under contract number: W81XWH-11-2-0184. The authors declare no conflict of interest. S.H.I.K. is an inventor listed on US Patent No. 7,22,179, US Patent No. 7,261,884, and international patent application PCT/US2004/043023, each titled "Live Genetically Attenuated Malaria Vaccine."